George A. Fisher Jr.
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Cancer Center
Contact Information
-
Academic Offices
Personal Information Tel (650) 725-9057Administrative Contact Diane Ayala Administrative Assistant Email Tel Work 650-725-9057
Professional Snapshot
Administrative Appointments
- Director, Cancer Clinical Trials Office (2004 - present)
Professional Education
| BS: | Stanford University, Biology (1976) |
| PhD: | Stanford University, Cancer Biology (1987) |
| MD: | Stanford University, Medicine (1987) |
| Residency: | Stanford University, Internal Medicine (1989) |
| Fellowship: | Stanford University, Medical Oncology (1993) |
Scientific Focus
Research Interests
The research program focuses on clinical trials involving new investigational agents for the treatment of a wide range of cancers. Active clinical trials include studies involving doxorubicin and taxol and agents that reverse resistance to these drugs, such as PSC 833.
Other interests include phase I and II studies using anti-sense DNA, targeting PKC-alpha in ovarian cancer and the role of gene-modified autologous T cells engineered to recognize the TAG-72 antigen on colon cancer cells.
Clinical Trials
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Recruiting
- Clinical and Pathologic Studies of Patients Undergoing Treatment with EGFR Inhibitors Recruiting
- Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Recruiting
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors Recruiting
- Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients Recruiting
Publications
- Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; (3): 665-72
- Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Dis Esophagus. 2009
- Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009; (22): 9010-5
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2009
- Pathological Response after Chemoradiation for T3 Rectal Cancer. Colorectal Dis. 2009
Trial Administration